US-based medical diagnostics company T2 Biosystems has raised $40m in its series E round including new investor, investment bank Goldman Sachs.
The money will help develop T2Candida, the company’s molecular diagnostic test of species-specific Candida fungal infections directly from whole blood.
In 2001, T2 closed a $23m series D round of financing led by US-based investment firm Aisling Capital.
Also participating in the consortium was Physic Ventures, a corporate venturing fund backed by, among others, consumer goods conglomerate Unilever, food…